Pharmacodynamics News and Research

RSS

AI-designed drug for Parkinson's begins first human trial

Insilico Medicine ("Insilico", HKEX: 3696), a clinical-stage biotechnology company powered by generative artificial intelligence (AI), today announced it has achieved the first clinical milestone in its co-development collaboration with Hygtia Therapeutics with the completion of first-in-human dosing in the Phase I study of ISM8969.

17 Jun 2026

Scientists rethink GLP-1 delivery to improve dosing, tolerability, and adherence

The review highlights nanocarriers, microspheres, hydrogels, microneedles, long-acting formulations, and co-formulations as promising but mostly early-stage strategies that still require stronger long-term clinical evidence.

27 May 2026

Understanding how biological sex and gender inequities contribute to suboptimal sepsis treatment

Sepsis continues to be a leading cause of mortality in ICUs worldwide. Despite advances in early detection and treatment, standardized antibiotic dosing frequently ignores patient-level variability-especially that associated with sex-related physiology and gender-influenced care disparities.

31 Oct 2025

Georgia State scientist receives $25,000 grant to develop mechanisms for treating obesity

Chong Hyun Shin, a research associate professor in the Institute for Biomedical Sciences at Georgia State University, has received a $25,000 grant to develop mechanisms for treating obesity and obesity-related metabolic dysfunctions.

23 Sep 2025

Different anti-PD-L1 antibodies show varied results in tumor growth inhibition

Immune checkpoint inhibitors (ICIs), a powerful form of immunotherapy, have revolutionized cancer treatment by unleashing the body's own immune system to fight tumors.

24 Jul 2025

Insilico Medicine begins clinical trial for AI-designed cancer drug ISM3412

Insilico Medicine, a clinical-stage biotechnology company driven by generative artificial intelligence (AI), today announces that the first patient has been dosed in a global multicenter clinical trial (NCT06414460) to evaluate ISM3412, a potentially best-in-class, AI-empowered MAT2A inhibitor with novel structure, in patients with locally advanced and metastatic solid tumors.

27 Jun 2025

Diabetes medication shows promise in cutting migraine days by more than half

A diabetes medication that lowers brain fluid pressure has cut monthly migraine days by more than half, according to a new study presented today at the European Academy of Neurology (EAN) Congress 2025.

20 Jun 2025

New switchable CAR-T therapy enters phase 1 trial for advanced breast cancer

The Calibr-Skaggs Institute for Innovative Medicines, the drug development division of Scripps Research, today announced a milestone in cancer treatment with the dosing of the first patient in a phase 1 trial (NCT06878248) evaluating CLBR001 + ABBV-461, a modular, switchable chimeric antigen receptor T cell (sCAR-T) therapy in patients with advanced or metastatic breast cancer who have no suitable treatment options.

18 Jun 2025

Deep B cell depletion offers new hope for rheumatologic and musculoskeletal diseases

CD19-CAR T-cell treatment is a novel option of deep B cell depletion with promising results across different rheumatologic and musculoskeletal diseases (RMD).

15 Jun 2025

New rifamycin drugs fight antibiotic-resistant lung infections more effectively

Researchers have developed next-generation rifamycin analogs that effectively kill both replicating and nonreplicating Mycobacterium abscessus while minimizing drug-drug interactions. Lead candidates UMN-120 and UMN-121 showed superior efficacy to current treatments in mouse models and retained potency against M. tuberculosis.

5 May 2025

New drug compound offers pain relief without opioid side effects

University of Florida scientists have helped identify a novel drug compound that selectively activates pain-altering receptors in the body, offering a potentially safer alternative to conventional pain medications.

8 Apr 2025

Microphysiological systems in drug discovery

NewsMedical speaks with CN Bio about the translatability between in vitro organ-on-a-chip (OOC) models, microphysiological systems, and their in vivo counterparts.

From CN Bio 26 Feb 2025

Insilico Medicine doses first patient in Phase I Trial of ISM6331 for mesothelioma

Insilico Medcine( "Insilico") , a clinical stage generative artificial intelligence (AI)-driven biotechnology company today announced the first patient has been dosed in the global multicenter Phase I Trial of ISM6331, a novel pan-TEAD inhibitor developed from Insilico's generative chemistry engine Chemistry42, for the treatment of mesothelioma and other solid tumors.

22 Jan 2025

Rice University leads development of innovative bioelectronic implant for obesity and diabetes

Rice University is part of a multiuniversity research team that has secured an award of up to $34.9 million from the Advanced Research Projects Agency for Health (ARPA-H) to accelerate the development of a bioelectronic implant designed to improve adherence for obesity and type 2 diabetes (T2D) treatment while reducing development and manufacturing costs.

3 Oct 2024